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Abstract
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Emerging evidence suggests that RANKL-induced changes in chromatin state are important for
osteoclastogenesis, but these epigenetic mechanisms are not well understood and have not been
therapeutically targeted. In this study we find that the small molecule I-BET151 that targets bromo
and extra-terminal (BET) proteins that “read” chromatin states by binding to acetylated histones
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strongly suppresses osteoclastogenesis. I-BET151 suppresses pathologic bone loss in TNFinduced inflammatory osteolysis, inflammatory arthritis, and post-ovariectomy models.
Transcriptome analysis identifies a MYC-NFAT axis important for osteoclastogenesis.
Mechanistically, I-BET151 inhibits expression of the master osteoclast regulator NFATC1 by
suppressing expression and recruitment of its newly identified upstream regulator MYC. MYC is
elevated in rheumatoid arthritis and its induction by RANKL is important for osteoclastogenesis
and TNF-induced bone resorption. These findings highlight the importance of an I-BET151inhibited MYC-NFAT axis in osteoclastogenesis, and suggest targeting epigenetic chromatin
regulators holds promise for treatment of inflammatory and estrogen deficiency-mediated
pathologic bone resorption.

Introduction

NIH-PA Author Manuscript

Osteoclasts are bone-resorbing cells important for bone homeostasis and pathological bone
resorption 1–5. M-CSF and RANKL are key factors required for differentiation of myeloid
lineage cells into osteoclasts. M-CSF promotes proliferation and survival of myeloid cells
and induces expression of RANK, the receptor for the key inducer of osteoclastogenesis
RANK ligand (RANKL). RANKL drives osteoclast differentiation by activating NF-κB,
MAPK and calcium signaling pathways to induce and activate transcription factor NFATc1,
a master regulator of osteoclastogenesis. RANKL-mediated signaling pathways are well
characterized 1 and RANKL-RANK interactions and downstream signaling pathways have
been targeted to treat osteoporosis and other bone diseases. Recently, it has become apparent
that RANKL-induced changes in chromatin state of osteoclast precursors are important for
osteoclastogenesis 6,7. However, epigenetic mechanisms that regulate osteoclast
differentiation have not been well clarified or therapeutically targeted.
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Epigenetic regulation, which includes modifications of DNA and chromatin, and expression
of noncoding RNA, plays an important role in physiological responses and pathological
conditions 8–10. Recent development of drugs that target epigenetic mechanisms, including
chromatin states, holds great promise in treating diseases such as cancers 11,12.
Bromodomain and extra-terminal (BET) proteins “read” chromatin states by binding to
acetylated histones (H-Ac) via bromodomains, and recruit additional chromatin regulators to
control gene transcription 13. Small molecule inhibitors which target the BET family have
been generated and inhibition of interaction of BET proteins with H-Ac using small
molecule inhibitors effectively suppresses tumor growth and inflammatory responses in
mouse models 13–19. These inhibitors show high specificity for their targets, specifically
binding the BET family proteins, and minimal systemic toxicity, suggesting a high potential
as effective and safe therapeutics 11,14,15,20. Here, we report that the small molecule
inhibitor I-BET151 that targets BET proteins effectively suppresses RANKL-induced
osteoclastogenesis. I-BET151 treatment suppressed in vivo bone loss in post ovariectomy
osteoporosis, inflammatory arthritis, and TNF-induced osteolysis mouse models.
Transcriptome analysis revealed that I-BET 151 inhibits NFATc1 expression by suppressing
MYC, and we identified a MYC-NFAT axis important for osteoclastogenesis that is targeted
by I-BET151. These findings implicate MYC and BET proteins in osteoclastogenesis, and
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suggest targeting epigenetic chromatin regulators as a new therapeutic approach for
controlling inflammatory bone resorption.
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Results
I-BET151 suppresses osteoclastogenesis in vitro and in vivo
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We tested the effects of BET bromodomain protein inhibition on osteoclast differentiation.
I-BET151 suppressed the differentiation of human and mouse osteoclast precursors (OCPs)
into multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cells in a dosedependent manner (Fig. 1a and Supplementary Fig. 1a). Accordingly, I-BET151 strongly
suppressed RANKL-induced expression of osteoclast-related genes such as CTSK (encodes
cathepsin K) and ITGB3 (encodes β3 integrin) in human and mouse OCPs (Fig. 1b and
Supplementary Fig. 1b). Reduced osteoclast formation did not result from changes in cell
viability or number, as assessed by MTT assays (Supplementary Fig. 2a, b). We next tested
whether I-BET151 could inhibit osteoclastogenesis in vivo. I-BET151 strongly inhibited
osteoclastogenesis and associated bone erosion in vivo in the TNF-induced supracalvarial
osteolysis model (Fig. 1c). Consistently, serum TRAP levels were lower in the I-BET151
treated group compared to the vehicle-treated control group (Fig. 1d). The reduction in in
vivo osteoclastogenesis was further confirmed using histomorphometric analysis to quantify
osteoclast numbers and surface area; both osteoclast surface area per bone surface (OcS/BS)
and osteoclast numbers per bone surface (NOc/BS) were significantly lower in the IBET151-treated group (Fig. 1e). Collectively, our results show that I-BET151 suppressed
osteoclastogenesis in vitro and in vivo.
I-BET151 protects mice from bone loss in OVX and arthritis
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To further test the efficacy of inhibiting BET proteins in the treatment of pathological bone
loss, we examined the effect of I-BET151 on bone loss in post-ovariectomy (OVX)
osteoporosis using a therapeutic experimental design. I-BET151 treatment was started four
weeks after OVX and continued for five weeks (Fig. 2a). Microcomputed tomography
(μCT) analysis revealed that I-BET151 treatment resulted in significantly increased bone
mass relative to vehicle-treated mice (Fig. 2b, c). Biomechanical properties of the femurs
were assessed by three-point bending and I-BET151 resulted in significantly increased bone
strength compared to vehicle treated ovariectomized mice (Fig. 2d). Histomorphometry
showed that I-BET151 decreased osteoclast numbers and surface area, supporting a
suppressive effect of I-BET151 on osteoclastogenesis (Fig. 2e). Consistent with previous
observations 21, the effects of I-BET in the OVX model with a therapeutic design were
similar to those of alendronate (Supplementary Fig. 3), a well-known anti-resorptive reagent
that targets osteoclasts with minimal direct effects on osteoblasts22. However, we tested the
effects of I-BET151 on osteoblast function. At the doses used to suppress osteoclastogenesis
in vivo, I-BET151 treatment did not significantly affect mineral apposition rate (MAR) and
bone formation rate (BFR) in ovariectomized mice (Supplementary Fig. 4). However, IBET151 suppressed in vitro osteoblast differentiation at concentrations 5-10-fold higher
than those required to suppress osteoclastogenesis (Supplementary Fig. 5). Thus, our results
suggest that I-BET151 therapeutically increases bone mass in the OVX model by
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suppressing osteoclastogenesis, but that supra-therapeutic doses have the potential to
suppress osteoblast-mediated bone formation.
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We next tested the effects of I-BET151 in K/BXN serum-induced arthritis, which models
the inflammatory effector phase of arthritis and is characterized by joint inflammation and
associated bone resorption 23. I-BET151-treated mice showed decreased joint swelling and
inflammation compared to vehicle-treated control mice (Fig. 3a, b and Supplementary Fig.
6). I-BET151-treated mice also showed decreased serum TRAP and decreased osteoclast
numbers in periarticular bone (Fig. 3c–e). K/BXN serum-induced arthritis is induced by
articular immune complexes and is highly dependent on interleukin-1 (IL-1)24 and
chemokine-mediated recruitment of neutrophils 25. To gain insights into how I-BET151
inhibits arthritic inflammation, we found that I-BET151 suppresses the induction of IL-1 by
immune complexes and various inflammatory stimuli, and also attenuates induction of
neutrophil chemokines by immune complexes or IL-1 (Supplementary Fig. 7). These results
suggest that in the K/BXN arthritis model, I-BET151 potently suppresses bone resorption by
a dual action of suppressing inflammation and directly targeting osteoclast differentiation.
Taken together, our results establish in vivo efficacy of I-BET151 and suggest that inhibition
of BET proteins may represent an effective therapeutic approach for suppressing bone loss.
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I-BET151 suppresses RANKL-induced NFATc1 expression
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To test in an unbiased manner for potential targets of I-BET151 that could yield insight into
its mechanisms of action, we performed a transcriptomic analysis using high throughput
RNA sequencing (Supplementary Fig. 8). I-BET151 suppressed expression of 465 RANKLinduced genes by >50% in two independent donors. These genes are depicted in the heat
map in Fig. 4a and listed in Supplementary Table 1; Supplementary Figs. 9–11 and legends
describe our analysis of transcriptomic data. Strikingly, of the 465 I-BET151 targets, 120
genes (26%) are target genes of the master regulator of osteoclastogenesis NFATC126
(Supplementary Table 2), and expression of NFATC1 itself was suppressed (Fig. 4a).
NFATc1 drives the early stages of osteoclast differentiation 27–29, NFATc1-deficient mice
develop severe osteopetrosis in vivo 30, and NFATc1-deficient cells are incapable of
differentiating into osteoclasts in vitro 28,29,31. Thus, we focused on understanding how IBET151 suppresses NFATC1 to downregulate osteoclastogenesis. In both human and mouse
OCPs, RANKL-induced NFATc1 mRNA and protein expression were inhibited by IBET151 in a dose-dependent manner (Fig. 4b, c and Supplementary Fig. 12a, b). I-BET151
also suppressed RANKL-induced expression of Blimp1, another key regulator of
osteoclastogenesis that is induced in part by NFATc132,33 (Fig. 4c and Supplementary Fig.
12a). Downregulation of NFATC1 expression by I-BET151 was not secondary to inhibition
of upstream RANK signaling (Supplementary Fig. 13a) or induction of known
transcriptional repressors of NFATC1 and osteoclast differentiation (Supplementary Fig.
13b), suggesting that I-BET151 either directly targets the NFATC1 locus or suppresses an as
yet unknown activator of NFATC1.
We next investigated mechanisms by which I-BET151 inhibits NFATC1 expression. IBET151 directly inhibits gene expression by disrupting binding of BET proteins to gene
loci14. However, using chromatin immunoprecipitation (ChIP) assays, we found that
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RANKL stimulation resulted in only a modest and not statistically significant recruitment of
BET proteins such as Brd4 to the NFATC1 locus (Fig. 4d). Although suppression of Brd4
recruitment (Fig. 4d) could contribute to suppression of NFATC1 expression, the weak
recruitment of Brd4 suggested that I-BET151 could also regulate NFATC1 expression
indirectly, potentially by suppressing the expression of a transcriptional activator required
for NFATC1 transcription. Such an indirect mechanism of action was supported by the
finding that I-BET suppressed RANKL-induced increases in the positive histone mark H4Ac at the NFATC1 locus (Fig. 4e), and, concomitantly, RANKL-induced recruitment to
NFATC1 of CBP, a key histone acetyltransferase (HAT) that mediates histone acetylation
(Fig. 4f). Decreased recruitment of CBP to the NFATC1 promoter suggests that I-BET151
may suppress a RANKL-induced transcription factor that is required to recruit HATs to
acetylate histones at NFATC1.
MYC-NFATc1 axis is important for osteoclast differentiation

NIH-PA Author Manuscript
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Although the currently appreciated important transcriptional regulators of
osteoclastogenesis34 are not known BET targets (Fig. 4a and Supplementary Fig. 13), the
transcription factor MYC is dependent on BET proteins 18,35 and was suggested to play a
role in osteoclastogenesis in RAW267.4 cells and mouse osteoclasts 36,37; however,
mechanisms by which MYC regulates osteoclastogenesis remain to be elucidated.
Strikingly, analysis of our transcriptomic data showed that 73 out of 465 (16%) of I-BET
targets correspond to MYC target genes (Supplementary Fig. 10), that MYC-dependent
cellular processes were suppressed by I-BET (Supplementary Figs. 9 and 11) and that MYCand NFAT-target genes overlap (Supplementary Fig. 10). These results support the idea that
a MYC-NFATC1 axis is important for osteoclastogenesis and thus we addressed the role of
MYC in our system. RANKL induced MYC (Fig. 5a) with similar kinetics as induction of
NFATc1 (Supplementary Fig. 14). I-BET151 abrogated RANKL-induced MYC expression
in human and mouse OCPs (Fig. 4a, 5a and Supplementary Fig. 15). To examine the role of
MYC in human OCPs, we treated cells with MYC inhibitor 10058-F4 38 or knocked down
MYC expression using siRNAs. Inhibition of MYC suppressed osteoclast differentiation
(Fig. 5b). We then tested whether MYC regulates the expression of NFATC1. MYC
inhibitor 10058-F4 inhibited RANKL-induced NFATC1 mRNA and protein expression in
dose-dependent manner in human and mouse OCPs (Fig. 5c, d and Supplementary Fig. 16).
Consistently, siRNA-mediated knockdown of MYC inhibited osteoclastogenesis and
RANKL-induced NFATc1 expression (Supplementary Fig. 17). Furthermore, ChIP assays
showed that RANKL stimulation induced recruitment of MYC to the NFATC1 promoter,
supporting direct regulation of NFATC1 by MYC (Fig. 5e). This RANKL-induced
occupancy of MYC at the NFATC1 promoter was effectively suppressed by I-BET151 (Fig.
5e). Inhibition of MYC decreased RANKL-induced H4-Ac at the NFATC1 promoter (Fig.
5f) in a manner parallel to decreased H4-Ac after I-BET151 treatment (Fig. 4e). These
results indicate that MYC is required for the induction of H4-Ac at the NFATC1 promoter.
Accordingly, MYC inhibition resulted in similar decreases in RANKL-induced recruitment
of CBP to NFATC1 (Fig. 5g). These results establish inhibition of MYC as a mechanism by
which I-BET151 regulates NFATC1, and support a role for MYC in osteoclastogenesis. We
previously reported that the expression of NFATC1 protein is increased in synovial OCPs of
rheumatoid arthritis (RA) patients 39, which have a higher potential for differentiating into
Nat Commun. Author manuscript; available in PMC 2015 May 13.
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osteoclasts 40. To investigate a potential role for MYC in vivo, we first examined MYC
expression in RA synovial OCPs. Quantitative RT-PCR analysis showed significantly
increased MYC expression in RA synovial CD14+ OCPs relative to disease controls, and a
parallel increase in NFATC1 mRNA (Fig. 5h). These results suggested a role for MYC in
osteoclastogenesis in inflammatory settings, which we further investigated using the TNFinduced supracalvarial osteolysis model. Similar to I-BET151 treatment, the MYC inhibitor
10058-F4 suppressed TNF-induced serum TRAP (Fig. 5i) and significantly reduced both
osteoclast surface area per bone surface (OcS/BS) and osteoclast numbers per bone surface
(NOc/BS) (Fig. 5j). Taken together, these results reveal MYC as an important factor in
osteoclastogenesis and suggest targeting MYC as a new therapeutic strategy to control bone
resorption.

Discussion
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Cytokines, receptors, signaling pathways and transcription factors that regulate
osteoclastogenesis have been extensively characterized 1,41, resulting in the identification of
therapeutic targets, such as RANKL and NFATC1, for the treatment of pathological bone
resorption 2–4. Emerging evidence suggests that chromatin states and related epigenetic
mechanisms that control how information encoded in DNA is expressed play an important
role in osteoclastogenesis 6,7,31. As many chromatin regulators are enzymes or ‘readers’ that
can be targeted by conventional small molecule approaches 11, this opens up new
therapeutic opportunities for suppression of osteoclastogenesis and pathologic bone
resorption. In this study, we show that I-BET151 inhibits osteoclast differentiation and
suppresses in vivo osteoclastogenesis and pathologic bone resorption in three distinct disease
models: TNF-induced inflammatory osteolysis, inflammatory arthritis, and post ovariectomy
low estrogen-mediated osteoporosis. Mechanistically, I-BET151 inhibited expression of the
master osteoclast regulator NFATC1 by suppressing expression and recruitment of its
upstream regulator MYC. MYC was elevated in rheumatoid arthritis synovial macrophages
and its induction by RANKL was important for osteoclastogenesis and TNF-induced bone
resorption. These results highlight the importance of an I-BET151-inhibited MYC-NFATC1
axis in osteoclastogenesis and pathologic bone resorption.
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Epigenetic mechanisms contribute to regulation of the expression of genes, and therapies
targeting epigenetic marks including DNA methylation and histone modifications such as
acetylation and methylation show therapeutic efficacy in several diseases and various
disease models11,12. In preclinical studies the related compounds I-BET151 and I-BET762,
and JQ1, appear safe and highly efficacious in treatment of NUT midline carcinoma, acute
myeloid leukemia, and multiple myeloma 15,18,42 and I-BET76214 is currently in clinical
trials (clinicaltrials.gov reference NCT01587703). We have demonstrated therapeutic
efficacy of I-BET151, a compound that targets an epigenetic mechanism important for
osteoclastogenesis, in increasing bone mass and strength in the standard post OVX model of
osteoporosis. While our manuscript was under revision, the related BET inhibitor JQ1 was
reported to suppress osteosarcoma-mediated bone remodeling by suppressing the function of
both osteoclasts and osteoblasts 43. As we have found that 5-10-fold higher concentrations
of I-BET151 are required to suppress osteoblast differentiation than osteoclastogenesis
(Supplementary Figs. 1 and 5), the differences in results, namely the lack of suppression of
Nat Commun. Author manuscript; available in PMC 2015 May 13.
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osteoblast function in vivo in our study, may be explained by differences in dosing or
pharmacokinetics of these two BET inhibitors. Alternatively, it is possible that distinct
pathogenic mechanisms in inflammatory or low estrogen-mediated bone loss versus tumormediated bone remodeling5 result in differential responses to BET inhibitors. Overall our
results in the post-ovariectomy model that I-BET151 suppressed osteoclastogenesis and
bone resorption but minimally affected bone formation suggest a therapeutic window in
which I-BET151 can exert beneficial effects on bone mass.

NIH-PA Author Manuscript

I-BET151 effectively suppressed osteoclastogenesis and pathologic bone resorption in
inflammatory disease models. Inflammatory bone resorption can be refractory to established
antiresorptive therapies 3,44, such as bisphosphonates, that target osteoclasts. In the K/BxN
arthritis model, I-BET151 suppressed inflammation as well as bone resorption. Thus, IBET151 offers the advantage of both suppressing inflammation, thus indirectly dampening
osteoclastogenesis, and directly suppressing osteoclast differentiation. BET inhibitors have
been shown to suppress induction of inflammatory secondary response genes by bacterial
lipopolysaccharide (LPS)14 and we have extended this work to show that I-BET151
suppresses immune complex- and IL-1-induced expression of cytokines and neutrophil
chemoattractants that are important for inflammatory arthritis. The combined effect of
suppressing inflammation and osteoclastogenesis suggests targeting BET proteins may be
effective in suppressing pathological bone resorption that occurs in inflammatory settings.
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BET inhibitors may have different therapeutic targets in various diseases11. One such target
is MYC and BET inhibitors have therapeutic applications in MYC-driven disorders, which
have otherwise been refractory to various therapeutic strategies to target MYC. Our results
suggest that in osteoclasts I-BET151 works at least in part by suppressing MYC and
targeting a newly described MYC-NFAT axis important for osteoclastogenesis. MYC has
been previously implicated in osteoclastogenesis but the mechanism by which MYC
regulates osteoclastogenesis was not clear36,37. Our investigation of mechanisms of IBET151 action revealed a role for MYC in osteoclast differentiation and inflammatory bone
resorption. One mechanism of MYC action was direct binding to and activation of NFATC1
expression, although it is possible that MYC also promotes osteoclastogenesis by additional
mechanisms that remain to be investigated. In summary, our results on the importance of
BET proteins and MYC in osteoclastogenesis open new lines of investigation in the
understanding and therapeutic targeting of pathological bone resorption.

Methods
Mice and analysis of bone phenotype
Six week-old female C57BL/6 were purchased from The Jackson Laboratory (Bar Harbor,
ME). All animal experiments were approved by the Hospital for Special Surgery
Institutional Animal Care and Use Committee (IACUC). All animals were randomly
assigned into experimental groups. For ovariectomy (OVX) -induced bone loss model,
sixteen week-old sham-operated or ovariectomized CD-1 mice were purchased from Charles
River Laboratory (Wilmington, MA). I-BET151 was prepared in 10% KLEPTOSE®
(Roquette Pharma) following the manufacturer’s instructions. Ovariectomized mice were
randomly divided into two groups (vehicle vs. I-BET; n=12 per group). To analyze the
Nat Commun. Author manuscript; available in PMC 2015 May 13.
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therapeutic effect of I-BET151, either vehicle or I-BET151 (30mg kg−1) was administrated
intraperitoneally (i.p.) once per day beginning 4 weeks after surgery. I-BET151 or vehicle
injection was continued for five weeks. After five-week treatment, femurs were isolated and
micro–computed tomography (μ-CT) analysis45 was performed at the Musculoskeletal
Repair and Regeneration Core Center in Hospital for Special Surgery as described
previously 46, and all samples were included in the analysis conducted in a blinded manner.
For arthritis experiments, K/BxN serum pools were prepared as described previously47.
Arthritis was induced by intraperitoneal injection of 100 μl of K/BxN serum on days 0 and
2. Arthritic mice were divided into 2 groups (vehicle vs. I-BET151; n=9 mice per group) and
were administered vehicle or I-BET151 (40 mg kg−1) once on days 0 and 2 and twice per
day from day 3 to day 6. Control group (n=9) only received vehicle but not arthritic serum.
The severity of arthritis was monitored by measuring the thickness of both the wrist and
ankle joints using dial-type calipers (Bel-Art Products). For each animal, joint thickness was
calculated as the sum of the measurements of both wrists and both ankles. Joint thickness
was represented as the average for every treatment group. For inflammatory osteolysis
experiments, we used an established mouse model, the TNF-induced supracalvarial
osteolysis model 48 with minor modifications. In brief, TNF was administrated daily at the
doses indicated in the figure legends to the calvarial periosteum of mice for four to five
consecutive days. The mice were then sacrificed for the collection of serum and calvarial
bones for sectioning. For histopathologic assessment, mice were euthanized, and the hind
paws and calvarial bones were harvested and fixed in 4% paraformaldehyde for 2 days.
These samples were decalcified with 10% neutral buffered EDTA (Sigma-Aldrich) and
embedded in paraffin. To assess osteoclastogenesis and bone resorption, sections were
stained with TRAP (tartrate-resistant acid phosphatase) and hematoxylin for osteoclast
visualization, and histomorphometric analysis was performed with the BioQuant image
analysis system (Nashville, TN, USA) using standard procedures 49. Osteoclasts were
identified as TRAP+ cells that were multinucleated and adjacent to bone. As markers for
osteoclast formation and bone resorption, serum TRAP5b was measured with the RatLaps
enzyme immunoassay (EIA) kit (Immunodiagnostic Systems) following the manufacturer’s
instructions.

NIH-PA Author Manuscript

Three-point bending test
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The whole bone strength of the femur was measured in bending. Femurs were loaded in
three-point bending to failure50. The bones were positioned with the posterior aspect resting
on the supports (6 mm span) and the load was applied to the anterior mid-diaphysis at a rate
of 0.1 mm/s (Bose Enduratec). The bending strength (maximum moment) and stiffness were
determined from the applied load and displacement data. All samples were included in the
analysis conducted in a blinded manner.
Reagents
Human and murine M-CSF, sRANKL and TNF were purchased from Peprotech (Rocky
Hill, NJ). I-BET was synthesized by GlaxoSmithKline (UK) as previously described15,51,52.
MYC inhibitor 10058-F4 was purchased from Sigma-Aldrich. The MTT assay kit was
purchased from Roche, and cell viability was measured following the manufacturer’s
instructions. The antibodies (1:1000) used for immunoblotting are as follows: NFATc1(BD
Nat Commun. Author manuscript; available in PMC 2015 May 13.
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Pharmagen; 556602); c-myc and p38 (Santa Cruz Biotechnology; sc-764 and sc535); Lamin
B (Abcam; ab16048); phospho-ERK, IκBα, phospho-p38 and Blimp1 (Cell Signaling; 9101,
9242, 9215, 9115).
Cell culture
Peripheral blood mononuclear cells were obtained from blood leukocyte preparations
purchased from the New York Blood Center by density gradient centrifugation with Ficoll
(Invitrogen, Carlsbad, CA) using a protocol approved by the Hospital for Special Surgery
Institutional Review Board. Monocytes were obtained from peripheral blood using antiCD14 magnetic beads, as recommended by the manufacturer (Miltenyi Biotec Auburn, CA).
Monocyte-derived osteoclast precursors (OCPs) that express RANK were obtained by
culturing for one day with 20 ng ml−1 of M-CSF (Peprotech) in α-MEM medium
(Invitrogen) supplemented with 10 % fetal bovine serum (FBS, Hyclone), and the purity of
monocytes was >97%, as verified by flow cytometric analysis.
Osteoclast differentiation
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Human CD14+ cells were incubated with 20 ng ml−1 of M-CSF for one day to generate
OCPs. For human osteoclastogenesis assays, cells were added to 96 well plates in triplicate
at a seeding density of 5×104 cells per well. Osteoclast precursors were incubated with 20 ng
ml−1of M-CSF and 40 ng ml−1of human soluble RANKL for five additional days in α-MEM
supplemented with 10 % FBS. Cytokines were replenished every 3 days. On day 6, cells
were fixed and stained for TRAP using the Acid Phosphatase Leukocyte diagnostic kit
(Sigma) as recommended by the manufacturer. Multinucleated (greater than 3 nuclei),
TRAP-positive osteoclasts were counted in triplicate wells. For mouse osteoclastogenesis,
bone marrow (BM) cells were flushed from femurs of mice and cultured with murine MCSF (20 ng ml−1, Peprotech) on petri dishes in α-MEM supplemented with 10% FBS after
lysis of RBCs using ACK lysis buffer (Cambrex, Walkersville, MD). Then, the nonadherent cell population was recovered the next day and cultured with murine M-CSF (20
ng ml−1) for three additional days. We defined this cell population as mouse OCPs. For
murine osteoclastogenesis assays, we plated 2×104 OCPs per well in triplicate wells on a 96
well plate and added M-CSF and RANKL (100 ng ml−1) for an additional 6 days, with
exchange of fresh media every 3 days. Imaging was performed with a 10X objective.
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Gene expression analysis
For real time PCR, DNA-free RNA was obtained using the RNeasy Mini Kit from QIAGEN
with DNase treatment, and 0.5 μg of total RNA was reverse transcribed using a First Strand
cDNA Synthesis kit (Fermentas, Hanover, MD). Real time PCR was performed in triplicate
using the iCycler iQ thermal cycler and detection system (Applied Biosystems, Carlsbad,
CA) following the manufacturer’s protocols. Expression of the tested gene was normalized
relative to levels of GAPDH.
RNA-sequencing
Total RNA was first extracted using RNeasy mini kit (Qiagen). True-seq sample preparation
kits (Illumina) were then used to purify poly-A transcripts and generate libraries with

Nat Commun. Author manuscript; available in PMC 2015 May 13.

Park-Min et al.

Page 10

NIH-PA Author Manuscript

multiplexed barcode adaptors. All samples passed quality control analysis on a Bioanalyzer
2100 (Agilent). Paired-end reads (50 × 2 cycles, ~75×106 reads per sample) were obtained
on an Illumina HiSeq 2500/1500 in the Weill Cornell Medical College Genomics Resources
Core Facility. The TopHat program (v 1.2.0) was used to align the reads to the UCSC Hg19
human reference genome, while the Cufflinks program (v. 0. 93) allowed for measurements
of transcript abundance (represented by Fragments Per Kilobase of exon model per Million
mapped reads (FPKM)). Genes and transcripts with FPKM values lower than five were not
included in the analysis. Pearson correlation analysis and heatmaps was generated using R
(3.0.2). The RNA sequencing data have been deposited to the Sequence Read Archive
(http://www.ncbi.nlm.nih.gov/sra/) and assigned study number SRP047069.
Chromatin Immunoprecipitation (ChIP)
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ChIP was performed as previously described 14. Briefly, 2 × 107 human primary OCPs were
fixed by adding formaldehyde directly to the medium to a final concentration of 1 % for 5
min. Cells were harvested, washed, and lysed. Chromatin was sheared by sonication to a
length of approximately 500 base pairs using a Bioruptor sonicator (Diagenode). Sheared
chromatin was precleared and then immunoprecipitated with antibodies; c-myc (Abcam;
ab56), Brd4 (Bethyl Lab; A301-985A), pan acetyl-H4 (Millipore; 06-866), and CBP
(Abcam; ab2832). Immune complexes were subsequently collected and washed, and DNA
crosslinking was reversed by heating at 65°C overnight. Following proteinase K digestion,
DNA was recovered using the PCR purification kit (Qiagen) and real time PCR was
performed to detect the occupancy of target proteins. Signals obtained from the ChIP are
divided by signals obtained from an input sample. This input sample represents the amount
of chromatin used in the ChIP. The primer sequences are listed in Supplementary Table 3.
Statistical analysis
All statistical analyses were performed with Graphpad Prism 5.0 software using the 2-tailed,
unpaired t-test (two conditions), one-way or two-way ANOVA for multiple comparisons
(more than two conditions) with posthoc Tukey test. p<0.05 was taken as statistically
significant.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. I-BET151 inhibits osteoclastogenesis
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a. Human OCPs (CD14+ monocytes cultured overnight with M-CSF (20 ng ml−1)) were
treated with DMSO (vehicle control, labeled 0) or I-BET151 at the indicated concentrations
for 1hr prior to addition of RANKL (40 ng ml−1). After 5 days of culture, TRAP-positive,
multinucleated (more than three nuclei) cells were counted in triplicate. The number of
osteoclasts generated by RANKL alone is set as 100% for each individual blood donor.
Upper panel, Representative results from one of more than three experiments. Lower panel,
Data are shown as mean ± SEM from aggregate data from 9 independent donors. **: P <
0.01, ***: P < 0.001 by two-way ANOVA. b. Human OCPs were cultured as in a for 5 days
and mRNA was measured using real-time PCR. mRNA levels were normalized relative to
GAPDH mRNA. Representative results from at least three independent experiments are
shown. c–e. TNF-induced osteolysis model. TNF (70 μg per kg body weight) was injected
over calvarial periosterium for four consecutive days, during which time either vehicle
control or I-BET151 (40 mg kg −1 body weight) in 10 % KLEPTOSE® was administrated
intraperitoneally (i.p.) once per day. Data shown are from 6 mice per group. c. TRAP
staining of histological sections obtained from control or I-BET151 treated mice after
supracalvarial TNF administration. Scale bar: 100 μm. d. ELISA measurement of serum
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TRAP. *: P < 0.05 by one-way ANOVA. e. Histomorphometric analysis. Osteoclast number
per bone surface (N.Oc BS−1). Osteoclast surface area per bone surface (OcS BS−1). All
data are shown as mean ± SEM. *:P < 0.05 by t-test.
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Figure 2. I-BET 151 increases bone mass and strength in ovariectomized mice
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a. A schematic diagram illustrating the therapeutic experimental design. b–c. Therapeutic
effect of the BET bromodomain protein inhibitor, I-BET151 on post ovariectomy bone loss
(n=12 per group). Sham-operated mice (Sham). b. Representative images showing
trabecular architecture by micro-computed tomography (μCT) reconstruction in the distal
femurs. Scale bars, 1 mm. c. μCT measurements for the indicated parameters in distal
femurs. Bone volume (BV/TV), trabecular space (Tb.Sp.), trabecular number (Tb.N.) and
trabecular thickness (Tb.Th.) were determined by μCT analysis. d. 3-point bending test of
femurs. e. Histomorphometric analysis of tibia. Osteoclast number per bone surface (N.Oc
BS−1). Osteoclast surface area per bone surface (OcS BS−1). All data are shown as mean ±
SEM * P <0.05, ** P <0.01. One-way ANOVA with a posthoc Tukey test was performed.
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Figure 3. I-BET151 attenuates K/BxN serum–induced arthritis

NIH-PA Author Manuscript

Arthritis was induced in C57BL/6 mice and I-BET151 was administered as described in
Methods. a. Time course of joint swelling in the presence and absence of I-BET151
treatment. Values are the mean ± SEM of 6 mice per group. ***: P < 0.001 by two-way
ANOVA. b. Histology of ankle joints of mice examined 11 days after the first arthritogenic
serum injection. Hind paws were fixed and decalcified, and ankle joint sections were
prepared and stained with hematoxylin, fast green, and Safranin O. Scale bar: 500μm c.
Serum TRAP levels were measured 7 days after arthritis induction. *: P < 0.05 by two-way
ANOVA. d. TRAP staining of histological sections obtained from control or I-BET151
treated arthritic mice. Blue square (inset) shows an enlarged image. Scale bar:100μm e.
Histomorphometric analysis. Osteoclast number per bone surface (N.Oc BS−1). Osteoclast
surface area per bone surface (OcS BS−1). All data are shown as mean ± SEM. *:P < 0.05
by t-test.
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Figure 4. I-BET151 inhibits NFATC1 expression

Human OCPs were treated with DMSO or I-BET151 for 1 hr, and then cultured with
RANKL (40 ng ml−1) for one day. a. upper panel: Heat map of RNA-seq FPKM values for
465 genes which were induced > 2-fold by RANKL and whose expression was suppressed
by >50% by I-BET151 in two independent donors as shown Supplementary Fig. 8. Lower
panel: box plot depicting FPKM values. (n=2) b. mRNA was measured using real-time PCR
and normalized relative to GAPDH mRNA. Results are shown as means ± SD of triplicate
determinants. c. Immunoblot of whole-cell lysates using NFATc1, Blimp1 and p38
antibodies. Same samples were loaded into two gels and p38 was served as a loading control
for each gel. Suppression of NFATc1 expression by I-BET151 was observed in at least 10
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independent experiments. Images have been cropped for presentation; full size blots are
shown in Supplementary Figure 18. d–f. Human OCPs were treated with DMSO (vehicle
control) or I-BET151 (500 nM) for 1 hr, and RANKL (40ng ml−1) was added for additional
24 hrs. Chromatin immunoprecipitation (ChIP) analysis of the NFATC1 promoter for Brd4
(d), acetylated H4 (e), or CBP (f). All data are shown as mean ± SD. Representative results
from at least three independent experiments are shown.
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Figure 5. I-BET151 suppresses RANKL-induced MYC expression
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a. Human OCPs were treated with DMSO or I-BET151 at the indicated concentrations for 1
hr, and then cultured with RANKL (40 ng ml−1) for one day (n=4). Analysis of expression
of MYC mRNA by real time-PCR. All data are shown as mean ± SEM. ***:P < 0.001 by
One-way ANOVA. b. (n=4) Osteoclastogenesis assay. Human OCPs were cultured with
either DMSO (vehicle control) or 10058-F4 at the indicated doses for 1 hr prior to RANKL
stimulation, and TRAP-positive multinucleated (more than three nuclei) cells were counted
5 days after RANKL addition. Upper panel, Representative results obtained from one donor
are shown. Lower panel, Data are shown as means ± SEM. c–d. Cells were cultured with
10058-F4 at the indicated doses for 1hr, and RANKL was then added for 2 days. c.
Immunoblot of whole cell lysates with NFATc1 and p38 antibodies. Images have been
cropped for presentation; full size blots are shown in Supplementary Figure 18. d. NFATc1
mRNA was measured by real-time PCR. mRNA levels were normalized to the expression of
GAPDH. e–g. ChIP analysis for MYC (e), acetylated H4 (f), or CBP (g) at the NFATC1
promoter in human OCPs. Representative results from three independent experiments are
shown. All data are shown as mean ± SD. h. MYC and NFATC1 expression in RA synovial
macrophages mRNA from synovial CD14+ cells from rheumatoid arthritis patients (n=16)
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or sero-negative arthritis disease control patients (n=11) was measured using real-time PCR.
mRNA levels were normalized relative to the expression of GAPDH. All data are shown as
mean ± SEM.*: P < 0.05; by t-test. i–j. TNF-induced supracalvareal osteolysis. n=6. TNF
(83 μg per kg body weight) was injected over calvarial periosterium for five consecutive
days, and either vehicle (DMSO) or 10058-F4 (30 mg kg−1) was administrated
intraperitoneally (i.p.) once per day. i. The concentration of serum TRAP measured by
ELISA. j. Histomorphometric analysis of calvaria from either vehicle or 10058-F4 treated
mice; osteoclast number per bone surface (N.Oc BS−1) and osteoclast surface area per bone
surface (OcS BS−1). All data are shown as mean ± SEM. *:P < 0.05 by t-test.
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